In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bridge Medical: Oops-less Medicine

Executive Summary

The subject of medical mistakes has drawn increased attention over the last five years, culminating in the November 1999 Institute of Medicine's report, which made front page news and triggered responses from President Clinton and Congress, as well as the medical establishment and the health care industry. Of particular interest to pharmaceutical and medical products companies is the problem of medication errors, which appear to be increasing for a variety of reasons, ranging from the complexities posed by ever-increasing numbers of drugs and delivery regimens, to more basic factors such as indecipherable physician handwriting and the increased pressure resulting from medical staffing reductions. Whatever the cause, one thing is clear: medication errors are a systemic problem not given to any one quick fix. With the potential for errors occurring at every stage of the medication delivery chain--prescribing, processing, dispensing, and administering drugs--there's plenty of room for companies with potential solutions. Yet, existing information and automated drug distribution systems only incidentally address the problem of medication errors. Bridge Medical, a start-up focused exclusively on developing systems to prevent medication errors, is looking to correct mistakes no matter where they originate by concentrating on the final step in the drug delivery process: the patient's bedside. Bridge recently parted ways with its founder, choosing to move in a different direction that will bring it into more direct competition with large health care information technology players. The company is betting that having a technological headstart and being the only pure-play medication-error company will enable it to successfully navigate what is rapidly becoming a crowded and heavily scrutinized market.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts